AdvaMed pushes for changes in proposed device ID plan

By Mark Hollmer AdvaMed wants the FDA to make a number of changes in its plan to mandate unique barcodes on all medical devices, in order to make the implementation more affordable ...

Boston Scientific jumps into renal denervation with $425M Vessix buy

By Damian Garde In all the gushing about the market potential of renal denervation technology, Boston Scientific ($BSX) has long been on the outside looking in. That’s about ...

FDA experts give Novartis’ Cushing’s drug unanimous endorsement

By John Carroll An FDA panel of outside experts gave Novartis ($NVS) some good news going into its R&D day today. The panel provided a unanimous thumbs up for Signifor (pasireotide), ...

Catalyst Pharma shares collapse after addiction drug flops in PhIIb

By John Carroll Catalyst Pharmaceutical Partners ($CPRX) says that its cocaine addiction therapy flopped in a Phase IIb study, missing primary and secondary endpoints and triggering ...

BioCryst scraps $235M late-stage flu drug program backed by feds

By John Carroll After years of research work backed by a multimillion-dollar federal contract, BioCryst ($BCRX) reported today that it is halting enrollment on its late-stage study ...

After cashing in on life-saving boast, biotech stayed mum on patient death

By John Carroll Back in August, Israel’s Pluristem Therapeutics ($PSTI) breathlessly announced that its stem cell therapy had saved the life of a 54-year-old woman teetering ...

Novartis R&D spotlights blockbuster hopefuls, promises 14 big approvals

By John Carroll Staring down some deep-seated worries about looming generic competition and serious doubts about its upbeat assessment of a pivotal trial earlier this week, Novartis ...

UPDATE 1-India’s Ranbaxy beats estimates on higher sales, forex gain

* Net profit 7.5 bln rupees vs estimate 2.92 bln rupees * North America sales rise 60 pct, India up 13 pct * Foreign exchange gains at 3.93 billion rupees MUMBAI, Nov 8 (Reuters) – ...

Vical’s Allovectin: Update On The Phase III Trial

By Theodore Cohen In its press release Wednesday morning, November 7, 2012, Vical Incorporated (VICL) announced that a comprehensive sweep of all active clinical sites in its Phase ...

Immune Pharmaceuticals and EpiCept Corporation Agree to Merge

HERZLIYA-PITUACH, Israel & TARRYTOWN, N.Y.–(BUSINESS WIRE)– Regulatory News: Immune Pharmaceuticals Ltd. (“Immune”), a privately held Israeli company, and EpiCept ...

Ariad’s on the Launchpad

By Keith Speights Ariad Pharmaceuticals (Nasdaq: ARIA  ) is on the launchpad. That’s the main message from the company’s third-quarter results announced on Nov. 7. ...

Auxilium Falls Most in Year as Crooked-Penis Deal Ends

By Drew Armstrong Auxilium Pharmaceuticals Inc. (AUXL), the maker of a drug to treat an abnormal curvature of the penis, fell the most in three months after announcing its partnership ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS